<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02240017</url>
  </required_header>
  <id_info>
    <org_study_id>13 URO 02</org_study_id>
    <nct_id>NCT02240017</nct_id>
  </id_info>
  <brief_title>A Study Evaluating Chemotherapy With Fractionated Cisplatin/Gemcitabine Versus Carboplatin/Gemcitabine in the Treatment of Advanced or Metastatic Urothelial Cancer With Impaired Renal Function.</brief_title>
  <acronym>VEFORA</acronym>
  <official_title>Randomized, Multicenter, Phase II/III Study, Evaluating Fractionated Cisplatin Chemotherapy/Gemcitabine Versus Carboplatin/Gemcitabine in the Treatment of Advanced or Metastatic Urothelial Cancer With Impaired Renal Function.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II/III, multicenter, randomized study which includes 420 patients on six
      years + 3 years follow up. 92 patients will be included during the phase II ; additional 328
      patients will be included.

      Patients with an advanced or metastatic urothelial cancer with impaired renal function will
      be randomized in one of the two following chemotherapy arm:

        -  Fractionated Cisplatin + Gemcitabine.

        -  Carboplatin + Gemcitabine.

      The main objective of the part II study will be to evaluate the efficacy and the safety of a
      chemotherapy with a doublet platinum salt compound/Gemcitabine with fractionated Cisplatin or
      Carboplatin in this population.

      The main objective of the part III study will be to compare the efficacy in terms of overall
      survival of a chemotherapy with a doublet platinum salt/Gemcitabine with fractionated
      Cisplatin or Carboplatin in this population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2015</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase II: Efficacy - Rate of non progression at the end of treatment (C6D21).</measure>
    <time_frame>5 years.</time_frame>
    <description>Progression is defined according to RECIST (Response Evaluation Criteria in Solid Tumors) criteria V1.1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase III: Overall survival (in months).</measure>
    <time_frame>9 years.</time_frame>
    <description>Overall survival is defined as the time from randomization until death or last follow up news (censured data).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Tolerance - Percentage of patients for whom at least one of the 3 defined tolerance criteria (see description) is observed.</measure>
    <time_frame>5 years.</time_frame>
    <description>Defined tolerance criteria :
Postponement of chemotherapy &gt; or = 2 weeks.
Alteration of renal function.
Need to decrease twice Gemcitabine dose on day 1 for : NCI CTC (National Cancer Institut Common Toxicity Criteria) grade III or IV non-hematologic toxicity, hematologic toxicity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase II and III: Objective response.</measure>
    <time_frame>Phase II: 5 years ; Phase III: 9 years.</time_frame>
    <description>Objective response (ie complete or partial response) will be evaluated according to RECIST v1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II and III: Tolerance according to NCI toxicity scale (version 4.0).</measure>
    <time_frame>Phase II: 5 years ; Phase III: 9 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II and III: Geriatric evaluation using questionnaires.</measure>
    <time_frame>Phase II: 5 years ; Phase III: 9 years.</time_frame>
    <description>The geriatric assessment will be evaluate using the following questionnaires: G8 (oncodage) , ADL (activity of daily living), CIRSG (cumulating illness rating scale geriatric) , MMS (mini-mental score), IADL (instrumental activities of daily living), GDS (geriatric depression scale), MNA (mini-nutritional assessment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II and III: Quality of life using the EORTC QLQ - C30 questionnaire (European Organization for research and treatment of Cancer - Quality of life questionnaire).</measure>
    <time_frame>Phase II: 5 years ; Phase III: 9 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II and III: Pharmacokinetics - Platin concentrations</measure>
    <time_frame>At cycles 1 and 2 day 1 - 5 mn before the end of infusion, one hour after the end of infusion, 3 hours (arm A) or 4 hours (arm B) after the end of infusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II and III: Pharmacogenetics, exploration of cytidine deaminase activity and study of its genetic polymorphisms.</measure>
    <time_frame>Prior to the initial dose on cycle 1 day 1.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II and III: Progression free survival.</measure>
    <time_frame>Phase II: 5 years ; phase III: 9 years.</time_frame>
    <description>Progression free survival will be evaluated according to RECIST v1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II and III: Overall survival.</measure>
    <time_frame>Phase II: 5 years ; Phase III: 9 years.</time_frame>
    <description>Overall survival is defined as the time from randomization until death from all causes combined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II and III: Time to treatment failure.</measure>
    <time_frame>Phase II: 5 years ; Phase III: 9 years.</time_frame>
    <description>Time to treatment failure is defined as the time from randomization to treatment discontinuation, whatever its cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Advanced Urothelial Cancer</condition>
  <condition>Metastatic Urothelial Cancer</condition>
  <arm_group>
    <arm_group_label>Carboplatin/Gemcitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fractionated Cisplatin/Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin AUC (area under curve) 4,5 at day 1 of each cycle until 6 cycles.</description>
    <arm_group_label>Carboplatin/Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fractionated Cisplatin</intervention_name>
    <description>Cisplatin 35mg/m² at day 1 and day 8 of each cycle until 6 cycles.</description>
    <arm_group_label>Fractionated Cisplatin/Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine 1000mg/m² at day 1 and day 8 of each cycle until 6 cycles.</description>
    <arm_group_label>Carboplatin/Gemcitabine</arm_group_label>
    <arm_group_label>Fractionated Cisplatin/Gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. . Age &lt; or = 18 years, patients aged 75 years or more will benefit from a geriatric
             assessment.

          2. . Advanced or metastatic urothelial cancer confirmed histologically or cytologically.

          3. . Patients liable to receive a first -line chemotherapy for advanced or metastatic
             urothelial carcinoma.

          4. . Measurable disease according to RECIST criteria V1.1.

          5. . Patients who received neoadjuvant or adjuvant chemotherapy based on platinum salt
             must have completed treatment at least 6 months before entering the study.

          6. . Performance status &lt; or = 2.

          7. . Life expectancy &gt; 3 months.

          8. . Patients with creatinine clearance between 40 and 60 ml / min ( according to
             Cockcroft and Gault ).

          9. . Patients having no contra-indication to overhydration.

         10. . Satisfactory hematological tests: Neutrophils &gt; 1.5 G / l Platelets &gt; 150 G / l ,
             hemoglobin ≥ 10 g / dl.

         11. . Satisfactory liver function tests: total bilirubin &lt; 1.5 x ULN (upper limit of
             normal), AST (aspartate aminotransferase) and ALT (alanine aminotransferase)&lt;or = 2.5
             x ULN (or 5 x ULN if liver metastases).

         12. . In case of prior radiotherapy, a minimum of 14 days must relapse between the end of
             radiotherapy and study entry.

         13. . For women of childbearing age , use an effective contraceptive method to study entry
             and for the duration of the study and 6 months after the last dose of study treatment
             ; For sexually active fertile men having a partner of childbearing age using effective
             contraception for the duration of the study and 6 months after the last dose of study
             treatment.

         14. . Patient affiliated to a social security system in France.

         15. . Patient signed informed consent before inclusion in the study and before any
             specific procedure for the study.

        Exclusion Criteria:

          1. . Any concomitant or previous malignancy within 5 years prior to the study ( with the
             exception of basal cell or squamous cell carcinoma in situ).

          2. . Pregnant or lactating women.

          3. . Patients with brain metastases or meningeal or symptoms suggestive of such secondary
             locations.

          4. . Bisphosphonate or Denosumab treatment initiated within 28 days prior to
             randomization into the study or patient who have started such treatment during the
             study ( a bisphosphonate or denosumab treatment initiated within a period longer than
             28 days before randomization may be continued without change during the study ).

          5. . Other concomitant cancer (radiation therapy, radiopharmaceutical agent
             chemotherapy).

          6. . Patients with uncontrolled infection.

          7. . Patients with peripheral neuropathy grade&gt; 1, whatever the origin or patients with
             hearing loss.

          8. . Patient with unstable disease (eg: unstable diabetes, poorly controlled hypertension
             , congestive heart failure or myocardial infarction within 3 months prior to study
             entry).

          9. . Known hypersensitivity to study drugs.

         10. . Treatment with any other investigational drug within 30 days before inclusion.

         11. . Any psychological condition , familial, sociological or geographical not to comply
             with medical monitoring and / or procedures in the study protocol.

         12. . Patient protected by law.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Loic MOUREY, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Claudius Regaud</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Loïc MOUREY, MD</last_name>
    <phone>+33(0)561424548</phone>
    <email>mourey.loïc@claudiusregaud.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>INSTITUT DE CANCEROLOGIE DE L'OUEST - Site Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie ABADIE-LACOURTOISIE, MD</last_name>
      <phone>33241352734</phone>
      <email>sophie.abadie-lacourtoisie@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie ABADIE-LACOURTOISIE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chru Besancon - Hopital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tristan MAURINA, MD</last_name>
      <phone>33381668166</phone>
      <email>tmaurina@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Tristan MAURINA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guilhem ROUBAUD, MD</last_name>
      <phone>33556333341</phone>
      <email>g.roubaud@bordeaux.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Guilhem ROUBAUD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence JOLY, PhD</last_name>
      <phone>02 31 45 50 02</phone>
      <email>f.joly@baclesse.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuel SEVIN, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain LADOIRE, MD</last_name>
      <phone>33380737506</phone>
      <email>sladoire@cgfl.fr</email>
    </contact>
    <investigator>
      <last_name>Sylvain LADOIRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH VERSAILLES - Hôpital André Mignot</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine ABRAHAM, MD</last_name>
      <phone>33139638909</phone>
      <email>cabraham@ch-versailles.fr</email>
    </contact>
    <investigator>
      <last_name>Christine ABRAHAM, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU LIMOGES - Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabrina FALKOWSKI, MD</last_name>
      <phone>33555056100</phone>
      <email>sabrina.falkowski@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Sabrina FALKOWSKI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aude FLECHON, MD</last_name>
      <phone>33478782828</phone>
      <email>flechon@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Aude FLECHON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwénaëlle GRAVIS-MESCAM</last_name>
      <phone>04 91 22 37 40</phone>
      <email>gravisg@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ch Mont de Marsan</name>
      <address>
        <city>Mont de Marsan</city>
        <zip>40024</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme DAUBA, MD</last_name>
      <phone>05 58 05 10 10</phone>
      <email>jerome.dauba@ch-mt-marsan.fr</email>
    </contact>
    <investigator>
      <last_name>Jérôme DAUBA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Regional Du Cancer Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diego TOSI, MD</last_name>
      <phone>33467612304</phone>
      <email>diego.tosi@icm.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Diego TOSI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ap-Hp-Hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène GAUTHIER, MD</last_name>
      <phone>01 42 49 42 47</phone>
      <email>helene.gauthier@aphp.frphp.fr</email>
    </contact>
    <investigator>
      <last_name>Hélène GAUTHIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>INSTITUT DE CANCEROLOGIE DE L'OUEST - Site René Gauducheau</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric ROLLAND, MD</last_name>
      <phone>33240679976</phone>
      <email>frederic.rolland@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Frédéric ROLLAND, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest en Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aline GUILLOT, MD</last_name>
      <phone>33477917032</phone>
      <email>aline.guillot@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Aline GUILLOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de STRASBOURG</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe BARTHELEMY</last_name>
      <phone>03 88 11 67 28</phone>
      <email>philippe.barthelemy@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loïc MOUREY, PhD</last_name>
      <phone>33561424548</phone>
      <email>mourey.loic@claudiusregaud.fr</email>
    </contact>
    <investigator>
      <last_name>Loïc MOUREY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chru Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claude LINASSIER, MD</last_name>
      <phone>33247479919</phone>
      <email>claude.linassier@univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Claude LINASSIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yohann LORIOT, MD</last_name>
      <phone>33142114211</phone>
      <email>yohann.loriot@igr.fr</email>
    </contact>
    <investigator>
      <last_name>Yohann LORIOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2014</study_first_submitted>
  <study_first_submitted_qc>September 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2014</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urothelial cancer, renal function impaired.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

